Recent Updates
Recently added Catalysts
RIGL Positive Sentiment

Rigel to Participate in Upcoming September Investor Conferences

Tuesday, August 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals announced participation in investor conferences in September. CEO Raul Rodriguez and CFO Dean Schorno will present at these events, highlighting the company's focus on hematologic disorders and cancer. Interested parties can access live webcasts and recordings through Rigel's Investor Relations section. This engagement reflects Rigel's commitment to investor communication.
Price reaction · baseline $40.74 (2025-08-25 close) · hit pre-market · clean, no other RIGL news in the window
day 0 close · peak
+2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel Pharmaceuticals is actively engaging with investors.
  • Participation in multiple conferences indicates strong investor interest.
  • The company's focus on hematologic disorders and cancer is promising.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.,Aug. 26, 2025/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced thatRaul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:
To access the live webcasts or archived recordings of the Cantor and H.C. Wainwright Conference presentations, visit the Investor Relations section of the company's website atwww.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About RigelRigel Pharmaceuticals, Inc. (Nasdaq:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based inSouth San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visitwww.rigel.com.

Contact for Investors & Media:Investors:Rigel Pharmaceuticals, Inc.650.624.1232[email protected]

Media:David RosenArgot Partners646.461.6387[email protected]

Frequently Asked Questions

Who will represent Rigel at the investor conferences?

Raul Rodriguez, the CEO, and Dean Schorno, the CFO, will represent Rigel.

Where can I access the conference presentations?

The presentations can be accessed through Rigel's Investor Relations section on their website.

What is the focus of Rigel Pharmaceuticals?

Rigel focuses on developing therapies for hematologic disorders and cancer.

When are the investor conferences taking place?

The investor conferences are scheduled for September.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals investor conferences Raul Rodriguez Dean Schorno hematologic disorders
Last updated: Aug 26, 2025

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →